Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen V. Liu(Georgetown University), Leora Horn(Vanderbilt University), Mark L. McCleland(Revolution Medicines (United States)), Jorge Alatorre-Alexander, Sivuonthanh Lam(Chinese University of Hong Kong), Raffaele Califano(The Christie NHS Foundation Trust), Francesco Orlandi(Instituto Nacional del Tórax), Ying Cheng(Jilin Province Tumor Hospital), Martin Reck(German Center for Lung Research), Tony Mok(Chinese University of Hong Kong), Aaron S. Mansfield(Mayo Clinic), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Makoto Nishio(Japanese Foundation For Cancer Research), Yu Deng(Capital Medical University), Javier de Castro(Bayer (United States)), Arnaud Scherpereel(Inserm), Marina Chiara Garassino(University of Chicago), Jong Seok Lee(Brigham and Women's Hospital), See Phan, Ticiana Leal(University of Wisconsin Carbone Cancer Center)
Cited by 818
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k